The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
571
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Change from baseline in MSSBP at week 8
change from baseline MSSBP after 2, 4 and 12 weeks of treatment
change from baseline MSDBP after 2, 4, 8 and 12 weeks of treatment
proportion of patients reaching overall BP control (MSSBP < 140 mmHg and MSDBP < 90mmHg) after 12 weeks of treatment
evaluation of safety and tolerability after 12 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.